Disease Areas


    • Stimulation of uterine contractions
    • Serious fungal infections due to Scedosporium spp. and Fusarium spp.

    • Milk production and mastitis prevention
    • Invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients

    • Invasive aspergillosis
    • Candidemia in non-neutropenic patients
    ×

    Syntocinon®

    • Drug: Oxytocin 5 IU injectable solution, 40 IU nasal spray
    • Pharmaceutical form: injectable solution, nasal spray
    • Presentation: ampoules, flasks
    • Product availability: Argentina

    Authorized indications:

    Prepartum:

    • Induction of labor for medical reasons, eg in cases of prolonged gestation, premature rupture of membranes, pregnancy-induced hypertension (pre-eclampsia).
    • Stimulation of contractions in selected cases of uterine inertia.
    • Syntocinon may also be indicated in the early stages of pregnancy, as adjunctive therapy for incomplete, unavoidable abortion or incomplete, unavoidable or arrested abortion.

    Postpartum:

    • During cesarean section after removal of the child
    • Prevention and treatment of uterine atony and hemorrhage during postpartum

    Industria Suiza – Industria Francesa

    Leaflet
    ×

    VORINOVA®

    • Drug: Voriconazole 200 mg
    • Pharmaceutical form: coated tablets / powder for solution for perfusion
    • Presentation: box containing 10 coated tablets / 1 vial of 20 ml
    • Product availability: Argentina

    Authorized indications:

    Voriconazole is a broad-spectrum triazole antifungal drug indicated in adults and children two years of age and older, for: Treatment of invasive aspergillosis. Treatment of candidemia in non-neutropenic patients. Treatment of severe invasive Candida infections (including C. krusei) resistant to fluconazole. Treatment of serious fungal infections due to Scedosporium spp. and Fusarium spp. Voriconazole should be administered primarily to patients with progressive infections that are potentially life-threatening. Prophylaxis of invasive fungal infections in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.

    Spanish industry

    Leaflet

    Learn more about the company

    Legal disclaimer: the content of this web site has been created exclusively for healthcare professionals in order to keep them informed and guide them in the proper use of medications. All texts referring to prescription products correspond to the guidelines approved by the corresponding authority in each country where Celnova Pharma operates. This content has no promotional purposes and is not intended to replace healthcare professional recommendations. Celnova Pharma always recommends to consult a qualified healthcare professional for any inquiry regarding to a particular medical condition.